Strides Pharma Science is currently trading at Rs. 371.10, up by 11.75 points or 3.27% from its previous closing of Rs. 359.35 on the BSE.
The scrip opened at Rs. 362.95 and has touched a high and low of Rs. 373.50 and Rs. 357.00 respectively. So far 134205 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 550.40 on 22-Jan-2019 and a 52 week low of Rs. 337.85 on 24-Jul-2019.
Last one week high and low of the scrip stood at Rs. 393.70 and Rs. 355.45 respectively. The current market cap of the company is Rs. 3341.09 crore.
The promoters holding in the company stood at 31.24%, while Institutions and Non-Institutions held 49.51% and 19.25% respectively.
Strides Pharma Science’s board has approved an additional investment up to a maximum of $40 million over a period of 24 months for a controlling stake in Stelis Biopharma (Stelis).
The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides’ re-entry into sterile injectables business post the completion of the company’s non-compete period in December 2019.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
